ИШЕМИК ИНСУЛЬТДА ЙЎҒОН ИЧАКНИНГ МОРФОФУНКЦИОНАЛ ҲОЛАТИ ИММУНОГИСТОКИМЁВИЙ АСОСЛАРИ БЎЙИЧА БАХОЛАШ МЕЗОНИ
Ключевые слова:
иммуногистокимёвий текшириш, ишемик инсульт, йўғон ичакАннотация
Тадқиқотимизда текширишларида, ZO-1 оқсил миқдори камайиб кетгани учун бўёқ ранги жуда оч, хира ёки заиф (кучсиз мусбат — +) бўлиб қолади. Оғир шикастланишларда (масалан, инсультнинг энг авж олган пайтида ёки оғир колитда) айрим ҳудудларда ZO-1 экспрессияси бутунлай йўқолади (манфий реакция — 0). Соғлом гурухда ичаклар шиллиқ қаватидан турли хил токсик моддалар ва бактериал транслокация хавфини кескин камайтириш билан намоён бўлишини англатади. Йўғон ичак шиллиқ қавати асосан ёнбош ичак шиллиқ қавати сўрғичлари апикал қисми ва крипталари юзасини қопловчи мукоцитларни 99,3% да ZO-1 оқсилини кўп бўлиши юқори даражадаги экспрессияланиш намоён бўлди.
##plugins.themes.default.displayStats.downloads##
Библиографические ссылки
1. Qamar A. A. et al. Platelet count is not a predictor of the presence or development of gastroesophageal varices in cirrhosis //Hepatology. – 2008. – Т. 47. – №. 1. – С. 153-159.
2. Reiner W., Melissa G., Markus. Pathological bacterial translocation in liver cirrhosis // Journal of Hepatology. 2014. Vol. 60. P. 197–209.
3. Salek J. et al. Recurrent liver failure in a 25‐year‐old female //Liver Transplantation. – 2010. – Т. 16. – №. 9. – С. 1049-1053.
4. Sinclair M. et al. sarcopenia in cirrhosis–aetiology, implications and potential therapeutic interventions //Alimentary pharmacology & therapeutics. – 2016. – Т. 43. – №. 7. – С. 765-777.
5. Smith T. N., De Moraes A. G., Simonetto D. A. Cirrhosis Management in the Intensive Care Unit //Seminars in Liver Disease. – Thieme Medical Publishers, Inc., 2023.
6. Stauber R. E. et al. Human nonmercaptalbumin‐2: a novel prognostic marker in chronic liver failure //Therapeutic Apheresis and Dialysis. – 2014. – Т. 18. – №. 1. – С. 74-78.
7. Tandon P. et al. A practical approach to nutritional screening and assessment in cirrhosis //Hepatology. – 2017. – Т. 65. – №. 3. – С. 1044-1057.
8. Tandon P. et al. Exercise in cirrhosis: translating evidence and experience to practice //Journal of hepatology. – 2018. – Т. 69. – №. 5. – С. 1164-1177.
9. Tsien C. D., McCullough A. J., Dasarathy S. Late evening snack: exploiting a period of anabolic opportunity in cirrhosis //Journal of gastroenterology and hepatology. – 2012. – Т. 27. – №. 3. – С. 430-441.
10. Tsukanov V. V. et al. Роль эрадикации Helicobacter pylori в профилактике рака желудка //Терапевтический архив. – 2014. – Т. 86. – №. 8. – С. 124-127.
11. Valerio C. et al. Human albumin solution for patients with cirrhosis and acute on chronic liver failure: Beyond simple volume expansion //World journal of hepatology. – 2016. – Т. 8. – №. 7. – С. 345.
12. Van Vugt J. L. A. et al. Systematic review and meta-analysis of the impact of computed tomography–assessed skeletal muscle mass on outcome in patients awaiting or undergoing liver transplantation //American Journal of Transplantation. – 2016. – Т. 16. – №. 8. – С. 2277-2292.
13. Vincent J. L., De Backer D., Wiedermann C. J. Fluid management in sepsis: The potential beneficial effects of albumin //Journal of critical care. – 2016. – Т. 35. – С. 161-167.
14. Wang D. et al. Preoperative inflammatory markers of NLR and PLR as indicators of poor prognosis in resectable HCC //PeerJ. – 2019. – Т. 7. – С. e7132.
15. Who O. Traditional Medicine. Fact Sheet. 2007. no. 134, Revised May 2003
16. World Medical Association (2013). WMA Declaration of Helsinki – Ethical principles for medical research involving human subjects. Online. Retrieved 4 July 2021, from: https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/
17. World of Work Report 2013–Repairing the economic and social fabric. – 2013. -133р.
18. Zhang M. et al. Neutrophil-to-lymphocyte ratio and albumin: new serum biomarkers to predict the prognosis of male alcoholic cirrhosis patients //BioMed Research International. – 2020. – Т. 2020. – С. 1-7.
19. Zhao Y. et al. Early sorafenib‐related adverse events predict therapy response of TACE plus sorafenib: A multicenter clinical study of 606 HCC patients //International journal of cancer. – 2016. – Т. 139. – №. 4. – С. 928-937.
